Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339726 | 1.00 | PREP (0.42) | PREPDGAT1EPHX1USP2SMN1; SMN2 | |
| SCHEMBL7040763 | 0.87 | CTSK (0.38) | PREPEPHX1USP2SMN1; SMN2CA1 | |
| SCHEMBL7040760 | 0.87 | CTSK (0.38) | PREPEPHX1USP2SMN1; SMN2CA1 | |
| SCHEMBL8191256 | 0.85 | HPGD (0.39) | PREPEPHX1CA1CA2CTSK | |
| SCHEMBL8191259 | 0.85 | HPGD (0.39) | PREPEPHX1CA1CA2CTSK | |
| SCHEMBL19658018 | 0.84 | CYP1A2 (0.34) | USP2SMN1; SMN2CA1CA2CTSK | |
| SCHEMBL3419541 | 0.83 | MAPK1 (0.33) | USP2SMN1; SMN2CA1CA2CTSK | |
| SCHEMBL8189001 | 0.83 | SMN1; SMN2 (0.50) | USP2SMN1; SMN2CTSK | |
| SCHEMBL3419540 | 0.83 | MAPK1 (0.33) | USP2SMN1; SMN2CA1CA2CTSK | |
| SCHEMBL8189004 | 0.83 | SMN1; SMN2 (0.50) | USP2SMN1; SMN2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829011-B2 | 2-aminopyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-09 | — | — | US | disclosed |
| US-20110207717-A1 | 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207717-A1 | 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR2A, HTR6, HTR5A | PREP 1832/4885DGAT1 4238/4885EPHX1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.